CN108096260A - 一种含有溶血磷脂酸的拮炎剂 - Google Patents
一种含有溶血磷脂酸的拮炎剂 Download PDFInfo
- Publication number
- CN108096260A CN108096260A CN201711450291.4A CN201711450291A CN108096260A CN 108096260 A CN108096260 A CN 108096260A CN 201711450291 A CN201711450291 A CN 201711450291A CN 108096260 A CN108096260 A CN 108096260A
- Authority
- CN
- China
- Prior art keywords
- lysophosphatidic acid
- raw material
- scorching agent
- agent short
- money containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 title claims abstract description 21
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 title claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 16
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011787 zinc oxide Substances 0.000 claims abstract description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004471 Glycine Substances 0.000 claims abstract description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 6
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 4
- 229960004574 azelastine Drugs 0.000 claims abstract description 4
- 235000011187 glycerol Nutrition 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 3
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 3
- 229960002518 gentamicin Drugs 0.000 claims abstract description 3
- 229960005150 glycerol Drugs 0.000 claims abstract description 3
- 229960001296 zinc oxide Drugs 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 claims description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 239000001099 ammonium carbonate Substances 0.000 claims description 3
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000005868 electrolysis reaction Methods 0.000 claims description 3
- 238000006266 etherification reaction Methods 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000002309 gasification Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 150000001469 hydantoins Chemical class 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- -1 hydroxypropyl Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000008676 import Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003483 aging Methods 0.000 description 1
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种含有溶血磷脂酸的拮炎剂，由以下原料构成：山梨糖醇、羟丙甲纤维素、甘氨酸、聚乙二醇、氧化锌、甘油、庆大霉素、氮卓斯汀、溶血磷脂酸，与现有技术相比，本发明具有如下的有益效果：多种药物集成发挥协同作用，药效显著，控制疾病迅速有效，不仅能对皮肤炎症有效果显著的治疗功效，而且不会给患者带来痛苦，同时具有存放不分层，容器底部药不结块。
Description
技术领域
本发明是一种含有溶血磷脂酸的拮炎剂，属于药剂领域。
背景技术
溶血磷脂酸（1-酰基-2-羟基-sn-丙三醇-3-磷酸酯，LPA）是通过涉及磷脂酶A2和溶血磷脂酶D的若干酶促反应的作用由膜脂衍生得到的生物活性脂质介质。LPA在若干种细胞功能中发挥作用，例如：细胞增殖、分化、存活、迁移和侵袭。这些功能影响包括血管新生、伤口修复、纤维化、炎症和癌形成在内的许多生理和病理过程。
现有技术中，对于过敏性炎症的用药品种比较单一，使用不是很方便，一种药只能针对一个环节，不足以完全有效的控制疾病。在大多数情况下，需要同时两种以上抗过敏制剂联合使用，才能见效，使用和携带起来很不方便。单一的药物通常使用时间比较长，药效降低，副作用明显，即便是联合用药，时间久了增加了感染机会，易患细菌性结膜炎，治疗效果不稳定。
发明内容
针对现有技术存在的不足，本发明目的是提供一种含有溶血磷脂酸的拮炎剂，以解决上述背景技术中提出的问题。
为了实现上述目的，本发明是通过如下的技术方案来实现：一种含有溶血磷脂酸的拮炎剂，由以下原料构成：山梨糖醇、羟丙甲纤维素、甘氨酸、聚乙二醇、氧化锌、甘油、庆大霉素、氮卓斯汀、溶血磷脂酸。
进一步地，将电解法制得的锌锭加热至600～700℃熔融后，置于耐高温坩埚内，使之1250～1300℃高温下熔融气化，导入热空气进行氧化，生成的氧化锌经冷却、旋风分离，将细粒子用布袋捕集，即制得原料中的氧化锌。
进一步地，将配制好的53%葡萄糖水溶液加入高压釜，加入葡萄糖重量0.1%的镍催化剂，经置换空气后，在3.5MPa、150℃、pH8.2-8.4条件下加氢，终点控制残糖在0.5%以下，沉淀5min后，将所得山梨糖醇溶液通过离子交换树脂精制即得原料中的山梨糖醇。
进一步地，将精制棉纤维素用碱液在35-40℃处理半小时,压榨,将纤维素粉碎,于35℃进行老化,使所得的碱纤平均聚合度在所需的范围内。将碱纤维投入醚化釜,依次加入环氧丙烷和氯甲烷,在50-80℃醚化5h,最高压力1.8MPa，然后在90℃的热水中加入盐酸及草酸洗涤物料,使体积膨大，用离心机脱水，洗涤至中性,当物料中含水量低于60%时,以130℃的热空气流干燥至含5%以下，最后粉碎过20目筛得原料中的羟丙甲纤维素。
进一步地，将三聚甲醛加入碳酸铵和腈化钠的水溶液中，室温下搅拌溶解后于80-85℃下反应3h。得到乙内酰脲水溶液。然后直接加入30%NaOH水溶液，于170℃下水解3h。最后以阳离子交换树脂处理，得到原料中的甘氨酸。
本发明的有益效果：本发明的一种含有溶血磷脂酸的拮炎剂，多种药物集成发挥协同作用，药效显著，控制疾病迅速有效，不仅能对皮肤炎症有效果显著的治疗功效，而且不会给患者带来痛苦，同时具有存放不分层，容器底部药不结块。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施方式，进一步阐述本发明。
本发明提供一种技术方案：一种含有溶血磷脂酸的拮炎剂，由以下原料构成：山梨糖醇、羟丙甲纤维素、甘氨酸、聚乙二醇、氧化锌、甘油、庆大霉素、氮卓斯汀、溶血磷脂酸。
将电解法制得的锌锭加热至600～700℃熔融后，置于耐高温坩埚内，使之1250～1300℃高温下熔融气化，导入热空气进行氧化，生成的氧化锌经冷却、旋风分离，将细粒子用布袋捕集，即制得原料中的氧化锌。
将配制好的53%葡萄糖水溶液加入高压釜，加入葡萄糖重量0.1%的镍催化剂，经置换空气后，在3.5MPa、150℃、pH8.2-8.4条件下加氢，终点控制残糖在0.5%以下，沉淀5min后，将所得山梨糖醇溶液通过离子交换树脂精制即得原料中的山梨糖醇。
将精制棉纤维素用碱液在35-40℃处理半小时,压榨,将纤维素粉碎,于35℃进行老化,使所得的碱纤平均聚合度在所需的范围内。将碱纤维投入醚化釜,依次加入环氧丙烷和氯甲烷,在50-80℃醚化5h,最高压力1.8MPa，然后在90℃的热水中加入盐酸及草酸洗涤物料,使体积膨大，用离心机脱水，洗涤至中性,当物料中含水量低于60%时,以130℃的热空气流干燥至含5%以下，最后粉碎过20目筛得原料中的羟丙甲纤维素。
将三聚甲醛加入碳酸铵和腈化钠的水溶液中，室温下搅拌溶解后于80-85℃下反应3h。得到乙内酰脲水溶液。然后直接加入30%NaOH水溶液，于170℃下水解3h。最后以阳离子交换树脂处理，得到原料中的甘氨酸。
作为本发明的一个实施例：本发明的一种含有溶血磷脂酸的拮炎剂，多种药物集成发挥协同作用，药效显著，控制疾病迅速有效，不仅能对皮肤炎症有效果显著的治疗功效，而且不会给患者带来痛苦，同时具有存放不分层，容器底部药不结块。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点,对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (9)
1.一种含有溶血磷脂酸的拮炎剂，其特征在于：由以下原料构成：山梨糖醇、羟丙甲纤维素、甘氨酸、聚乙二醇、氧化锌、甘油、庆大霉素、氮卓斯汀、溶血磷脂酸。
2.根据权利要求1所述的一种含有溶血磷脂酸的拮炎剂，其特征在于：将电解法制得的锌锭加热至600～700℃熔融后，置于耐高温坩埚内，使之1250～1300℃高温下熔融气化，导入热空气进行氧化，生成的氧化锌经冷却、旋风分离，将细粒子用布袋捕集，即制得原料中的氧化锌。
3.根据权利要求1所述的一种含有溶血磷脂酸的拮炎剂，其特征在于：将配制好的53%葡萄糖水溶液加入高压釜，加入葡萄糖重量0.1%的镍催化剂，经置换空气后，在3.5MPa、150℃、pH8.2-8.4条件下加氢，终点控制残糖在0.5%以下，沉淀5min后，将所得山梨糖醇溶液通过离子交换树脂精制即得原料中的山梨糖醇。
4.根据权利要求1所述的一种含有溶血磷脂酸的拮炎剂，其特征在于：将精制棉纤维素用碱液在35-40℃处理半小时,压榨,将纤维素粉碎,于35℃进行老化,使所得的碱纤平均聚合度在所需的范围内。
5.将碱纤维投入醚化釜,依次加入环氧丙烷和氯甲烷,在50-80℃醚化5h,最高压力1.8MPa，然后在90℃的热水中加入盐酸及草酸洗涤物料,使体积膨大，用离心机脱水，洗涤至中性,当物料中含水量低于60%时,以130℃的热空气流干燥至含5%以下，最后粉碎过20目筛得原料中的羟丙甲纤维素。
6.根据权利要求1所述的一种含有溶血磷脂酸的拮炎剂，其特征在于：将三聚甲醛加入碳酸铵和腈化钠的水溶液中，室温下搅拌溶解后于80-85℃下反应3h。
7.得到乙内酰脲水溶液。
8.然后直接加入30%NaOH水溶液，于170℃下水解3h。
9.最后以阳离子交换树脂处理，得到原料中的甘氨酸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711450291.4A CN108096260A (zh) | 2017-12-28 | 2017-12-28 | 一种含有溶血磷脂酸的拮炎剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711450291.4A CN108096260A (zh) | 2017-12-28 | 2017-12-28 | 一种含有溶血磷脂酸的拮炎剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108096260A true CN108096260A (zh) | 2018-06-01 |
Family
ID=62213681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711450291.4A Pending CN108096260A (zh) | 2017-12-28 | 2017-12-28 | 一种含有溶血磷脂酸的拮炎剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108096260A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109646443A (zh) * | 2019-02-22 | 2019-04-19 | 潍坊医学院 | 溶血磷脂酸的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1068034A (zh) * | 1991-05-31 | 1993-01-20 | 普罗格特-甘布尔公司 | 用溶血磷脂酸调整皮肤皱纹的方法 |
| CN1509178A (zh) * | 2001-04-25 | 2004-06-30 | 碧欧塞根公司 | 一种包括溶血磷脂酸的药用组合物 |
| CN105816354A (zh) * | 2015-08-03 | 2016-08-03 | 杭州莱凡网络科技有限公司 | 一种添加有闪光片、镭射粉、人造钻石粉的指彩 |
| CN106721919A (zh) * | 2016-12-07 | 2017-05-31 | 紫花（广州）药业有限公司 | 一种口腔清洁口含片 |
-
2017
- 2017-12-28 CN CN201711450291.4A patent/CN108096260A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1068034A (zh) * | 1991-05-31 | 1993-01-20 | 普罗格特-甘布尔公司 | 用溶血磷脂酸调整皮肤皱纹的方法 |
| CN1509178A (zh) * | 2001-04-25 | 2004-06-30 | 碧欧塞根公司 | 一种包括溶血磷脂酸的药用组合物 |
| CN105816354A (zh) * | 2015-08-03 | 2016-08-03 | 杭州莱凡网络科技有限公司 | 一种添加有闪光片、镭射粉、人造钻石粉的指彩 |
| CN106721919A (zh) * | 2016-12-07 | 2017-05-31 | 紫花（广州）药业有限公司 | 一种口腔清洁口含片 |
Non-Patent Citations (2)
| Title |
|---|
| 周学良等: "《精细化学品大全 食品和饲料添加剂卷》", 31 December 2000, 浙江科学技术出版社 * |
| 张威: "山梨醇", 《小氮肥设计技术》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109646443A (zh) * | 2019-02-22 | 2019-04-19 | 潍坊医学院 | 溶血磷脂酸的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101182559B (zh) | 一种利用挤压辅助酶解小麦麸皮制备低聚木糖的方法 | |
| CN103468834B (zh) | 一种中性亚硫酸盐处理植物纤维制备低聚木糖的方法 | |
| CN104774887A (zh) | 一种玉米芯低聚木糖的制备方法 | |
| WO2011011907A1 (zh) | 一种植物来源d-氨基葡萄糖盐酸盐的制备方法 | |
| CN105646301A (zh) | 从大蒜中提取蒜氨酸联产蒜多糖和蒜粉的方法 | |
| CN110818751B (zh) | 一种硫酸氨基葡萄糖氯化钠复盐的制备方法 | |
| CN108096260A (zh) | 一种含有溶血磷脂酸的拮炎剂 | |
| CN103445187B (zh) | 一种莲藕藕节可溶性膳食纤维的制备方法 | |
| CN107286059A (zh) | 一种月桂酰精氨酸乙酯盐酸盐的制备方法 | |
| CN104725522A (zh) | 一种高温高压提取银耳多糖的方法 | |
| CN103130913A (zh) | 一种果胶钙及其生产方法与应用 | |
| CN106633200A (zh) | 一种羧甲基纤维素纳米复合膜的制备方法 | |
| CN105037564A (zh) | 一种微晶纤维素的制备方法 | |
| CN117304346B (zh) | 一种棉短绒纤维制备微晶纤维素的方法及其应用 | |
| CN102020723B (zh) | 一种从菊芋杆中连续提取低酯果胶、微晶纤维素的方法 | |
| CN108685798A (zh) | 一种婴儿滋润保湿乳 | |
| CN115466335B (zh) | 一种利用小麦麸皮提取多糖的工艺 | |
| CN106191167A (zh) | 一种利用酶解法制备木糖的生产工艺 | |
| CN106541485A (zh) | 由秸秆生产人造板材料时联产高附加值产品的方法 | |
| CN106334545B (zh) | 一种安全型颗粒状食品干燥剂的制备方法 | |
| JP2530337B2 (ja) | バガスからヘミセルロ−スを抽出する方法 | |
| CN107712245A (zh) | 一种低糖保健糖果及其制备方法 | |
| CN101269124A (zh) | 一种车前子多糖口服制剂、制备方法及用途 | |
| CN1821332A (zh) | 一种亚麻胶的生产方法 | |
| CN113480669A (zh) | 一种低松密度交联羧甲纤维素钠的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180601 |